Integral Molecular

Integral Molecular is a privately held, revenue-generating biotechnology company that has established itself as an industry leader in membrane protein and antibody discovery technologies. The company operates a dual business model, providing fee-for-service research tools and reagent platforms while also developing its own preclinical therapeutic antibody pipeline for out-licensing. Its core strength lies in tackling difficult membrane protein targets, which are implicated in a wide range of diseases but have been historically challenging for drug discovery. Recent milestones include FDA qualification progress for its Membrane Proteome Array and the advancement of several bispecific and antibody-drug conjugate candidates into preclinical development.

Specialized platforms for membrane protein research and antibody discovery, including the Membrane Proteome Array (MPA) for high-throughput specificity screening, MPS Antibody Discovery, Lipoparticles/VLPs for native protein presentation, and comprehensive epitope/paratope mapping services (Paratope-PLUS, CDR-Scanning).

As a membrane protein specialist, Integral Molecular competes with other antibody discovery CROs and platform companies (e.g., AbCellera, Distributed Bio) but is differentiated by its deep focus on native membrane protein presentation and characterization. In its therapeutic pipeline, it competes with numerous biopharma companies developing CLDN18.2 and GPRC5D-targeting therapies, requiring high differentiation for successful partnering.